We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
- Authors
Tahara, Junko; Shimizu, Kyoko; Otsuka, Nao; Akao, Junichi; Takayama, Yukiko; Tokushige, Katsutoshi
- Abstract
<bold>Purpose: </bold>New chemotherapies have become available for the treatment of advanced pancreatic cancer and have led to changes in its standard treatments. Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy.<bold>Methods: </bold>Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital. In this study, we retrospectively evaluated their clinical characteristics, survival outcomes and adverse events.<bold>Results: </bold>Twelve of the 27 patients were treated with FFX, and the other 15 patients were treated with G-nab. The disease control rate was 86.7% in the G-nab group and 75% in the FFX group. Median OS time was 8.9 months in the FFX group and 11.8 months in the G-nab group. The 1-year survival rate was 46.6% in the G-nab group and 16.6% in the FFX group. The second-line treatment rate was 40% in the G-nab group and 66.7% in the FFX group. The grade 3-4 neutropenia rate was 20% in the G-nab group and 25% in the FFX group. No patients developed febrile neutropenia, or severe nausea, diarrhea, or anorexia. The peripheral sensory neuropathy rate was 73.3% in the G-nab group and 75% in the FFX group.<bold>Conclusions: </bold>Although G-nab and FFX are effective treatments for advanced pancreatic cancer, the G-nab group had a higher 1-year survival rate, and G-nab can be more safely administered to older patients.
- Subjects
PACLITAXEL; PANCREATIC cancer treatment; MEDICATION safety; POPULATION aging; HOSPITAL care; THERAPEUTIC use of antineoplastic agents; PANCREATIC tumors; SURVIVAL; ALBUMINS; FOLINIC acid; RESEARCH; RESEARCH methodology; METASTASIS; DEOXYCYTIDINE; ANTINEOPLASTIC agents; RETROSPECTIVE studies; EVALUATION research; MEDICAL cooperation; FLUOROURACIL; COMPARATIVE studies; KAPLAN-Meier estimator
- Publication
Cancer Chemotherapy & Pharmacology, 2018, Vol 82, Issue 2, p245
- ISSN
0344-5704
- Publication type
journal article
- DOI
10.1007/s00280-018-3611-y